NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/29/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization65,160 mln
Float97.67 mln
Earnings Date07/30/2026
EPS
40.93
Exceptional
P / E
15.02
Moderately valued
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-2.56
Likely reliable
1-Year Forecast
833
Strong upside
Relative Strength
7
/ 100
Severely lagging
Business Description
Regeneron Pharmaceuticals is a New York-based company founded in 1988 that researches, makes, and sells prescription medicines for a wide range of serious health conditions, including eye diseases, cancer, heart disease, and rare disorders. Its portfolio includes well-known treatments such as EYLEA for vision-threatening retinal conditions, Dupixent for eczema and asthma, and Libtayo for certain skin cancers, among others. To expand its reach and capabilities, the company works alongside partners like Bayer, Alnylam, and Intellia Therapeutics to develop next-generation therapies, including gene-editing and RNA-based treatments targeting diseases of the eye, brain, and muscles.
